AstraZeneca, Valeant Pharmaceuticals deal

AstraZeneca granted Valeant exclusive, worldwide rights to develop and commercialize brodalumab, excluding undisclosed Asian territories. AZ will receive $100 million up front and is eligible for up to $345 million in milestones. Valeant will cover development and regulatory costs, and the partners would share profits. Valeant plans to submit regulatory applications in the U.S. and EU next quarter for brodalumab to treat moderate to severe psoriasis. ...